Idorsia Ltd (IDIA) - Total Assets
Based on the latest financial reports, Idorsia Ltd (IDIA) holds total assets worth CHF454.57 Million CHF (≈ $574.70 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Idorsia Ltd (IDIA) shareholders funds for net asset value and shareholders' equity analysis.
Idorsia Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Idorsia Ltd's total assets have evolved over time, based on quarterly financial data.
Idorsia Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Idorsia Ltd's total assets of CHF454.57 Million consist of 50.5% current assets and 49.5% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 21.0% |
| Accounts Receivable | CHF26.36 Million | 5.2% |
| Inventory | CHF62.65 Million | 12.4% |
| Property, Plant & Equipment | CHF216.92 Million | 42.9% |
| Intangible Assets | CHF23.47 Million | 4.6% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Idorsia Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Idorsia Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Idorsia Ltd's current assets represent 50.5% of total assets in 2024, a decrease from 82.3% in 2016.
- Cash Position: Cash and equivalents constituted 21.0% of total assets in 2024, down from 79.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 42.9% of total assets.
Idorsia Ltd Competitors by Total Assets
Key competitors of Idorsia Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Idorsia Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 0.53 | 8.12 |
| Quick Ratio | 0.83 | 0.35 | 8.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF61.03 Million | CHF-177.06 Million | CHF907.16 Million |
Idorsia Ltd - Advanced Valuation Insights
This section examines the relationship between Idorsia Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.65 |
| Latest Market Cap to Assets Ratio | 1.50 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | CHF505.89 Million |
| Market Capitalization | $759.27 Million USD |
Valuation Analysis
Above Book Valuation: The market values Idorsia Ltd's assets above their book value (1.50x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Idorsia Ltd's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Idorsia Ltd (2016–2024)
The table below shows the annual total assets of Idorsia Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF505.89 Million ≈ $639.59 Million |
+1.18% |
| 2023-12-31 | CHF500.00 Million ≈ $632.13 Million |
-44.70% |
| 2022-12-31 | CHF904.18 Million ≈ $1.14 Billion |
-39.03% |
| 2021-12-31 | CHF1.48 Billion ≈ $1.87 Billion |
+3.32% |
| 2020-12-31 | CHF1.44 Billion ≈ $1.81 Billion |
+42.94% |
| 2019-12-31 | CHF1.00 Billion ≈ $1.27 Billion |
-28.62% |
| 2018-12-31 | CHF1.41 Billion ≈ $1.78 Billion |
+8.89% |
| 2017-12-31 | CHF1.29 Billion ≈ $1.63 Billion |
+41.17% |
| 2016-12-31 | CHF915.12 Million ≈ $1.16 Billion |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more